Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchLosartanLosartan (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Losartan for COVID-19
5 studies from 78 scientists
665 patients in 2 countries
No significant improvements are seen in meta analysis to date.
COVID-19 Losartan studies. Jun 2024. c19early.org
0 0.5 1 1.5+ All studies -15% Mortality -16% Hospitalization -177% RCTs -15% RCT mortality -16% Early -2% Late -16% Favorslosartan Favorscontrol
Jun 13
Covid Analysis Losartan for COVID-19: real-time meta analysis of 5 studies
Meta analysis using the most serious outcome reported shows 15% [-42‑127%] higher risk, without reaching statistical significance. Currently all studies are RCTs. Currently there is limited data, with only 665 patients and only..
Dec 31
2022
Götberg et al., SSRN Electronic Journal, doi:10.2139/ssrn.4278529 Effect of Adding Losartan to Standard of Care Treatment on the Risk of Death and Icu Admission Among Hospitalized COVID-19 Patients: A Randomized Trial
77% lower ventilation (p=0.01) and 36% lower ICU admission (p=0.24). RCT 302 hospitalized COVID-19 patients showing lower mechanical ventilation but no significant difference in ICU admission or mortality with losartan treatment.
Oct 31
2022
Freilich et al., Contemporary Clinical Trials Communications, doi:10.1016/j.conctc.2022.100968 COVIDMED – An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients
533% higher mortality (p=0.49) and 160% longer hospitalization (p=0.3). RCT 15 hospitalized COVID-19 patients showing no significant differences with losartan treatment. The study was terminated early due to low enrollment.
Mar 19
2022
Mirjalili et al., BMC Cardiovascular Disorders, doi:10.1186/s12872-022-02548-2 Does Losartan reduce the severity of COVID-19 in hypertensive patients?
81% lower mortality (p=0.003) and 3% fewer cases (p=0.86). Retrospective study of 280 hypertensive patients in Iran showing lower mortality with losartan use in COVID-19 patients, however data is contradictory and unclear. The text and Figure 1 indicate that 179 of 280 patients were PCR+, however..
Mar 16
2022
Puskarich et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.2735 Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury
3% higher mortality (p=1), 27% higher ventilation (p=0.47), and 3% lower need for oxygen therapy (p=0.66). RCT 205 hospitalized COVID-19 patients showing no significant difference in lung injury (PaO2:FiO2 ratio) at day 7 with losartan treatment, and no difference in clinical outcomes including mortality. Losartan was associated with more adve..
Jul 31
2021
Puskarich et al., eClinicalMedicine, doi:10.1016/j.eclinm.2021.100957 A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19
2% higher ICU admission (p=1), 205% higher hospitalization (p=0.36), and 27% higher progression (p=0.74). RCT 117 symptomatic outpatients showing no significant difference in hospitalization, functional status, dyspnea, or viral load with losartan treatment. The trial was terminated early due to low event rates. Losartan 25mg twice daily for ..
May 11
2021
Geriak et al., Infectious Diseases and Therapy, doi:10.1007/s40121-021-00453-3 Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia
6% lower mortality (p=1), 53% lower ICU admission (p=0.6), 53% higher hospital discharge (p=0.6), and 10% shorter hospitalization. RCT 31 hospitalized COVID-19 patients with mild hypoxemia showing no significant difference in mechanical ventilation, ICU admission, or mortality with addition of losartan to standard care.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit